An interventional study of Elective induction of labor at 39 gestational weeks and 0 to 3 days in Pregnancy, Obesity and Parturition, sponsored by University of Aarhus. Completed at 12 sites in Denmark. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by University of Aarhus · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Obesity by University of Aarhus — 5 open to participants now, 7 under way, none of them phase 3. Obesity · University of Aarhus.
Among the 40 studies in Obesity by University of Aarhus, this one has the largest enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2020, is one of 24 with no phase, and was the 25th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →5 of the 40 studies in Obesity by University of Aarhus are open now, in 1 country. Recruiting first, the newest first:
University of Aarhus · Sites in Denmark
Ages 18+
University of Aarhus · Sites in Denmark
Ages 55–70 · Healthy volunteers
University of Aarhus · Sites in Denmark
Ages 18+ · Healthy volunteers
University of Aarhus · Sites in Denmark
Ages 18–75 · Healthy volunteers
University of Aarhus · Sites in Denmark
Ages 7–14 · Healthy volunteers
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,901 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 30 across the 26 interventional studies, 67 across the 14 observational. Of the 30 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Aarhus is the lead sponsor of 1,303 studies on the registry; 190 are open to participants now.
2 of the studies in Obesity by University of Aarhus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07463495University of AarhusThe Metabolic Effects of Oral Tributyrin Administration | 2026-12 |
| NCT07359625University of AarhusEffects of Ketone Bodies on Insulin Sensitivity | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 40 studies in Obesity by University of Aarhus, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The rate of overweight and obese women becoming pregnant is increasing. Obesity in pregnancy along with delivery by cesarean section in obese women is associated with several complications as compared to normal weight women. The longer the woman is pregnant, the longer she is at risk. In an otherwise low-risk pregnant woman at term, it is an ongoing clinical dilemma, whether the benefits of elective induction of labor and termination of the pregnancy will outweigh the potential harms from concomitant induction and delivery process. The proposed study is a randomized controlled study of elective induction versus expectant management in obese women. The study will be carried out as a national multicenter study with inclusion of 1900 participants from Danish delivery wards. The null hypothesis is that the caesarean section rate is similar with elective induction of labor at 39 weeks of gestation, compared with expectant management among pregnant women with pre- or early pregnancy BMI≥30.
Background The World Health Organization (WHO) defines overweight as a body mass index (BMI) of ≥25 kg/m2 and obesity as a BMI of ≥30 kg/m2. Overweight and obesity are rising dramatically worldwide. In fertile women, the prevalence of obesity is one third in the United States, 20% in the United Kingdom, and 12-13% in Denmark. The association between obesity in pregnancy and the risk of gestational complications increases with increasing BMI. Among other complications, obesity in pregnancy is associated with increased risk of caesarean delivery. Delivery by caesarean section further adds significant risks of wound infection or other infectious morbidity in obese women as compared to normal weight women. The longer the woman is pregnant, the longer the risk of pregnancy complications remains. In an otherwise low-risk pregnant woman at term, it is an on-going clinical dilemma, whether the benefits of elective induction of labor (eIOL) and termination of the pregnancy will outweigh the potential harms from the concomitant induction and delivery process. Regarding delivery complications, based on data from historical cohorts, eIOL has traditionally been associated with an increased risk of caesarean section and instrumental delivery. Therefore, expectant management has been the preferred clinical option. This interpretation has now been challenged by a randomized trial (ARRIVE) with >6000 low-risk pregnant women where eIOL at 39 weeks of gestation was associated with lower caesarean delivery rates. There are no randomized studies in obese women, but two larger observational studies did find lower odds of caesarean delivery in obese women with eIOL as compared to awaiting labor onset. Hence, a randomized trial that would compare caesarean delivery among obese women whose labor is induced with those expectantly managed is warranted. The proposed study will provide new and important knowledge into the area of induction of labor among overweight and obese women with potential great international impact for the future raising number of pregnant women in this subgroup.
With this trial, the investigators aim to compare the risk of caesarean section in obese (BMI ≥ 30 kg/m2), but otherwise low-risk women with eIOL as compared to expectant management.
Materials and methods
The study is a multicenter randomized controlled trial with an allocation ratio of 1:1 in the two following arms:
Comparison arm/expectant management: Waiting for spontaneous onset of labor unless a situation develops necessitating either induction of labor or caesarean section.
1900 low-risk pregnant women with a pre- or early pregnancy BMI ≥ 30 carrying a singleton pregnancy will be recruited from the Danish delivery wards. In each trial site, a physician investigator will be responsible for the enrolment, the electronically randomization, and data collection.
The primary endpoint is the caesarean section rate. Among others there will be secondary endpoints on instrumental delivery, onset of labor, methods of induction, perinatal and postpartum complications both maternal and neonatal along with data on women's experience on birth measured by a questionnaire survey four to six weeks post-partum.
Ethics The study will be conducted in accordance with the ethical principles outlined in the latest version of the 'Declaration of Helsinki' and the 'Guideline for Good Clinical Practice' related to experiments on humans. The Central Denmark Region Committee on Biomedical Research Ethics, and The Danish Health Authorities have approved the study.
Perspectives In perspective, more than 39% of the world's population is overweight and 13% are obese by the WHO classification. Pregnant overweight women are at increased risk of pregnancy and delivery complications, and there is a need to improve maternity care for this subgroup of women. The results of this trial have the potential to generate important knowledge for the improvement of delivery in obese women and they will add key information to an on-going discussion of the effects of labor induction before term. Any possible harm or disadvantage to the individual study participant is outweighed by the possible benefit to the increasing number of obese women who will be pregnant in the future.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Elective induction of labour at 39 gestational weeks and 0 to 3 days.
Procedure: Elective induction of labor at 39 gestational weeks and 0 to 3 days
Awaiting spontaneous labor.
Elective induction of labor (eIOL) according to local policies
Also known as: eIOL
Caesarean section
number (no.)
Time frame: At delivery
Mode of delivery if not by caesarean
* Vaginal delivery - no. * Vaginal assisted delivery - no.
Time frame: At delivery
Mode of delivery
* Caesarean section - percent * Vaginal delivery - percent * Vaginal assisted delivery - percent
Time frame: At delivery
Vaginal assisted delivery
* Forceps - no. * Ventouse - no.
Time frame: At delivery
Indication for caesarean section (more than one indication is possible)
* Labour dystocia - no. * Fetal distress - no. * Maternal request - no. * Suspected macrosomia - no. * Non-cephalic presentation - no. * Extensive vaginal bleeding - no. * Suspected uterine rupture - no. * Maternal or fetal complication/condition (free text) - no. * Other indication for caesarean section (free text) - no.
Time frame: At delivery
Indication for vaginal assisted delivery (more than one is possible)
* Labour dystocia - no. * Fetal distress - no. * Maternal request - no. * Other indication for assisted vaginal delivery (free text) - no.
Time frame: At delivery
Use of epidural
no.
Time frame: At delivery
Damage to internal organs (bladder, bowel or ureters)
no.
Time frame: At delivery to 30 days postpartum
Uterine scar dehiscense or rupture
no.
Time frame: At delivery
Complications
* Minor shoulder dystocia defined as the need for McRobert's maneuver - no. * Major shoulder dystocia defined as the need for procedures other than McRobert's maneuver - no. * Clinical suspicion of abruption of the placenta leading to an intervention in labour - no. * Cord prolapse - no. * Maternal fever defined as temperature \>38,2 / \>38,0 degrees celsius with / without epidural - no. * Perineal 3rd degree laceration - no. * Perineal 4th degree laceration - no. * Episiotomy - no.
Time frame: At delivery
Postpartum haemorrhage
* Blood loss \>500ml - no. * Blood loss \>1000ml - no. * Blood transfusion - no. Time Frame \[0-2 days postpartum\]
Time frame: 0-2 hours postpartum
Hysterectomy
no.
Time frame: At delivery to 30 days postpartum
Postpartum morbidity
* Puerperal infection treated in hospital - no. * Other severe postpartum conditions treated in hospital (free text) - no.
Time frame: 0-30 days postpartum
Maternal admission to Intensive Care Unit
no.
Time frame: Enrollment to 30 days postpartum
Maternal cardiopulmonary arrest
no.
Time frame: Enrollment to 30 days postpartum
Maternal death
no.
Time frame: Enrollment to 30 days postpartum
Primary neonatal composite including any of the following;
* Perinatal death (stillbirth and neonatal) * The need for respiratory support if admitted to a neonatal department (intubation and mechanical ventilation, oxygen, continuous positive airway pressure (CPAP), or high-flow nasal cannula (HNFC)). Time Frame \[within 72 hours after birth\] * Apgar score \< 4 at 5 minutes * Hypoxic-ischemic encephalopathy (defined as the need for therapeutic hypothermia) * Seizures * Infection (defined as antibiotic treatment continuously for 7 days minimum) * Meconium aspiration syndrome * Birth trauma (bone fracture, Duchenne-Erbs palsy, or retinal hemorrhage) * Intracranial or subgaleal hemorrhage * Hypotension requiring vasopressor support
Time frame: Enrollment to 28 days of life
Components of the primary neonatal composite will additionally be reported separately
* Perinatal death (stillbirth and neonatal) - no. * The need for respiratory support if admitted to a neonatal department (intubation and mechanical ventilation, oxygen, continuous positive airway pressure (CPAP), or high-flow nasal cannula (HNFC)). Time Frame \[within 72 hours after birth\] - no. * Apgar score \< 4 at 5 minutes - no. * Hypoxic-ischemic encephalopathy (defined as the need for therapeutic hypothermia) - no. * Seizures - no. * Infection (defined as antibiotic treatment continuously for 7 days minimum) - no. * Meconium aspiration syndrome - no. * Birth trauma (bone fracture, Duchenne-Erbs palsy, or retinal hemorrhage) - no. * Intracranial or subgaleal hemorrhage - no. * Hypotension requiring vasopressor support - no.
Time frame: Enrollment to 28 days of life
Neonatal trauma composite including any of the following;
* Birth trauma (bone fracture, Duchenne-Erbs palsy, or retinal hemorrhage) * Intracranial or subgaleal hemorrhage
Time frame: At delivery to 28 days of life
Neonatal asphyxia composite including any of the following;
* Apgar score \< 4 at 5 minutes * Umbilical cord pH-value \< 7.0 (allow missing data) * Umbilical cord standard base excess (sBE) \< -15.0 mmol/l (allow missing data) * Seizures * Hypoxic-ischemic encephalopathy (defined as the need for therapeutic hypothermia)
Time frame: At delivery to 28 days of life
Apgar score at 5 minutes
* Apgar score \<4 - no. * Apgar score of 4-7 - no.
Time frame: 5 minutes of life
Umbilical cord arterial and venous blood sample (allow missing data)
* pH-value \< 7.0 - no. * sBE \< -15.0 mmol/l - no.
Time frame: 0-30 minutes of life
Neonatal admission
no.
Time frame: 0-72 hours of life
Respiratory support during neonatal admission
* CPAP (y/n) - no. * HNFC (y/n) - no. * Oxygen supplement treatment (y/n) - no. * Ventilator treatment (y/n) - no.
Time frame: 0-28 days of life
Other treatment during neonatal admission
* Therapeutic hypothermia (y/n) - no. * Vasopressor support (y/n) - no. * Antibiotic treatment continuously for 7 days minimum (y/n) - no.
Time frame: 0-28 days of life
Neonatal characteristics 1
* Female sex - no. * Birth weight \> 4500 grams (y/n) - no.
Time frame: At delivery
Neonatal characteristics 2
\- Mean birth weight - grams
Time frame: At delivery
Maternal experience on birth
Childbirth Experience Questionnaire Scoring range is 1 to 4 where higher ratings reflect more positive experiences
Time frame: 4-6 weeks postpartum
Maternal postnatal depression
* Major Depression Inventory (MDI) * Edinburgh Postnatal Depression Score Scoring range is 1 to 4 where higher ratings reflect more positive experiences
Time frame: 4-6 weeks postpartum
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The final dataset will be publicly available in an anonymised form using an open data repository (i.e. CERN) or another equivalent database. All relevant trial-related documents will be shared along with the data.
Time frame: Beginning three months and ending three years after the publication of the last trial results.
Access criteria: Data will be available for any research purpose to all interested parties who have approval from an independent review committee. Interested parties will be able to request the data by contacting the trial sponsor. Authorship of publications emerging from the shared data will follow standard authorship guidelines and will include authors from the WINDOW study group depending on the nature of their involvement.
Ran from Oct 2020 to primary completion in Jul 2026, 68 months.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 68 months is above that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.